Introduction
SPARK閮2006撟渡皞蝢�銝寧�之摮賂�Prof. Daria Mochly-Rosen�蝡�蜓閬璅撟怠憭批飛���飛�����陌�������冗��������銵歇頞��16撟湛���������6����犖��蜀嚗蒂����������澈�����嚗��歇�����20��振撘�脫�撠�SPARK閮嚗PARK Global蝯��蝬風憭活頝典����降敺�撓��耦嚗璅��ranslational Scientists without Borders嚗����飛銵��璆剔��振嚗����������飛銵������閫�瘙箸獢�����陌��璆剜��嚗����犖憿摨瑯��
SPARK Taiwan雿蝚砌��絲憭PARK閮��銵�振嚗�僑�銵歇��蝚�10撟渡敞蝛�����300����摮貊��������������隞�振��PARK閮�銵�����������齒SPARK Asia Showcase蝑楊����暑������澈��
When life gives you lemons, make lemonade!���暑蝯虫��皞��疙瑼祆��停����������疙瑼祆�!��銝���隤姿隤�靘�撠�車銝���瘜�璈�蒂�������漲嚗��迤��璆剖振��撣�! 隞僑嚗���旨撟賊�隢Stanford SPARK �憪犖�PARK Global �憪犖銋���� Daria Mochly-Rosen ����澈憟孵�仃����瞈���犖敹�璈�����窄鞎游璆剔���������� Biodesign ��� SPARK 憒���鼠����������兢��隢銝寧�之摮睬iodesign Director�arsus Pharmaceuticals嚗����蟡其誨蝣潘�ARS嚗鈭Dr. Michael Ackermann隞晶Biodesign瘚����摨瑞��銋����迨憭�����隢�雿�振嚗tanford SPARK�����犖Prof. Kevin Grimes ������r. Jeewon Kim��澈�摨岫撽�身閮��晶蝢��蝘飛撣���迭餈PARK������陌�摮賊����閎��犖憯怠��PARK Symposium��
�����PARK Symposium�蝺��齒嚗����PARK璆剖葦��������澈嚗����������!
The SPARK Program founded by Professor Daria Mochly-Rosen in 2006 at Stanford University in USA. The main goal of this program is to translate the academic discoveries in the university into products that benefit patients and society. This program has been implemented for more than 16 years and has achieved an amazing success rate of over 60%. Its successful experience is shared all over the world. At present, more than 20 countries have introduced or are about to introduce the SPARK Program, and SPARK Global is gradually taking shape after multiple transnational meetings. The goal is to gather Translational Scientists without Borders, to improve human health by uniting academics and industry experts around the globe to generate an efficient, effective and exciting pathway for translation of academic discoveries and innovative solutions through education and project support.
SPARK Taiwan, as the first country where the SPARK Program is implemented overseas, has entered the tenth year of implementation and has helped over 300 biomedical research teams in the country with commercialization. At the same time, it is also committed to assisting the implementation of SPARK projects in other countries, including holding SPARK Asia Showcase and other multinational cooperation activities and experience sharing in Taiwan Biotechnology Month.
When life gives you lemons, make lemonade! That� exactly what entrepreneurs do. This year, it is honored to invite Prof. Daria Mochly-Rosen, the founder of Stanford SPARK and one of the founders of SPARK Global, to share her invaluable entrepreneurial experience in turning a failure into exciting new opportunities and a success. Have you wonder how Biodesign and SPARK work together to help patients? It is privileged to invite Dr. Michael Ackermann, the director of Biotechnology for the Stanford University Byers Center for Biodesign and Chairman of the Board of Tarsus Pharmaceuticals (NASDAQ: TARS) to introduce Biodesign process for health technology innovation. In addition, two of Stanford SPARK practitioners, the co-director Prof. Kevin Grimes and the program manager Dr. Jeewon Kim were invited to share on clinical trial design and the US Life science market introduction. New SPARK teams and those who are interested in the field of biomedical translation are welcomed to participate in the SPARK Symposium.
Due to the epidemic, SPARK Symposium will be held online. Thanks to SPARK professionals from all over the world for their enthusiastic support and sharing. We look forward to your participation online.
Date/Time:
[Taiwan Time] 2022/10/31(Mon) 09:00 AM ~12:35 PM
[SFO Time] 2022/10/30(Sun) 06:00 PM ~ 09:35 PM
Venue:
Online** The video URL will be notified by email 2 days before the symposium.
Organizer:
SPARK Taiwan Office, Science & Technology Policy Research and Information Center, National Applied Research Laboratories
Contact info:
sparktw@narlabs.org.tw (SPARK Taiwan Office)
Advisor ���雿�
Organizer 銝餉齒�雿�
Agenda
Date:
2022/10/31(Mon) 09:00 AM ~12:35 PM (Taiwan time);
2022/10/30(Sun) 06:00 PM ~ 09:35 PM(PDT)
Venue: ON-LINE
| Taiwan Time (SFO Time) |
Topics | Speakers |
|---|---|---|
| 09:00 ~ 9:30 AM (6:00 ~ 6:30 PM) |
Registration |
|
| 09:30 ~ 9:40 AM (6:30 ~ 6:40 PM) |
Opening Remarks |
Prof. Y. Jane Tseng Director, SPARK Taiwan Program |
| 9:40 ~ 10:20 AM (6:40 ~ 7:20 PM) |
Keynote Session-I How to Make Lemonade from Lemons; Turning a Failure Into a Success |
Prof. Daria Mochly-Rosen Founder and co-Director of SPARK At Stanford, |
| 10:20 ~ 11:00 AM (7:20 ~ 8:00 PM) |
Keynote Session-II Biodesign Process for Health Technology Innovation |
Dr. Michael Ackermann Director of Biotechnology for the Stanford |
| 11:00 ~ 11:10 AM (8:00 ~ 8:10 PM) |
Break |
|
| 11:10 ~ 11:50 AM (8:10 ~ 8:50 PM) |
Session I Clinical Trial Design |
Prof. Kevin Grimes Co-Director of SPARK At Stanford |
| 11:50 AM ~ 12:30 PM (8:50 ~ 9:30 PM) |
Session II A Brief Introduction to the US Life Science Market |
Dr. Jeewon Kim Program manager of SPARK At Stanford |
| 12:30 ~12:35 PM (9:30 ~9:35 PM) |
Closing Remarks |
Prof. Y. Jane Tseng Director, SPARK Taiwan Program |
Speakers
Prof. Daria Mochly-Rosen
Founder and Director of SPARK At Stanford,
Professor of Chemical and Systems Biology, Stanford University School of Medicine
Professor Daria Mochly-Rosen helps academics navigate the so-called �alley of death�� between drug discovery and development. Professor Mochly-Rosen founded The SPARK Program at Stanford in 2006 after having to leave academia to start a pharmaceutical company to translate her protein kinase C research into cardiovascular therapeutics. Challenging the academic dogma of how scientific discoveries should reach the pharmaceutical industry, the SPARK model has been implemented internationally and has resulted in a book about drug development from academia. Professor of Chemical and Systems Biology at Stanford, she leads a multi-disciplinary research lab that includes chemists, biochemists, biologists and physician scientists. She has published over 285 papers and over 36 patents and patent applications. Professor Mochly-Rosen is originally from Israel, where she received her doctorate in Chemical Immunology from The Weizmann Institute of Science.
Dr. Michael Ackermann
Director of Biotechnology for the Stanford
University Byers Center for Biodesign,.
Co-founder and Chairman of Tarsus Pharmaceuticals
Michael is Director of Biotechnology for the Stanford University Byers Center for Biodesign. He is also co-founder and serves as Chairman of the Board of Tarsus Pharmaceuticals (NASDAQ: TARS).�� Michael is also co-founder, former CEO, and serves on the board of Presidio Medical.�� Previously, he was co-founder and served as Chairman of Oyster Point Pharma, Inc. (NASDAQ: OYST). Prior to this, he was Vice President, Neurostimulation for Allergan (an AbbVie company), after serving as co-founder and CEO of Oculeve, Inc., which was acquired by Allergan, plc.�� Michael received a BE degree from Vanderbilt University and MS and PhD degrees from Case Western Reserve University. He is a graduate of the Stanford University Biodesign Fellowship and Vision Research Fellowship.�� He has more than 50 issued US patents and numerous patent applications and peer-reviewed publications.
Prof. Kevin Grimes
Co-Director of SPARK At Stanford
Professor of Chemical and Systems Biology,
Stanford University School of Medicine
Kevin Grimes, MD is Professor of Chemical and Systems Biology and Co-director of the SPARK Program at Stanford. While a Clinical Assistant Professor of Medicine at Stanford, he obtained an MBA at the Stanford Graduate School of Business. He was selected as a White House Fellow and served as Special Assistant to the Secretary of Defense. After 15 years in the biotech industry, he returned to Stanford. SPARK� mission is to advance promising discoveries to patient care; to educate faculty and trainees regarding the translational process; and to identify more efficient approaches to bring new therapies to patients. The SPARK methodology has been adopted by over 50 academic institutions world-wide. Grimes teaches graduate student courses on drug discovery and development and continues to teach and practice internal medicine. He received the David Rytand Award for Excellence in Clinical Teaching and the Faculty Award for Excellence in Graduate Teaching.
Dr. Jeewon Kim
Program manager of SPARK At Stanford
Jeewon Kim received her undergraduate degree at Seoul National University in Korea and worked at Daesang Ltd, a Food and Drug company in Korea. She did her doctoral work at UC Berkeley in the lab of Dr. Marc Hellerstein, where she developed a stable isotope biomarker to detect early phases of colon cancer. She subsequently worked as a consultant for startup company Kinemed Inc. Then as a postdoctoral fellow, she began drug development work in Dr. Daria Mochly-Rosen� lab at Stanford, studying the roles of different protein kinase C (PKC) isozymes in breast and prostate cancer. While in Dr. Mochly-Rosen� lab, she worked to develop small peptides as anticancer drugs. This work has resulted in multiple publications and review papers and identified the roles of PKCs in cancer proliferation, angiogenesis, migration and metastasis. She then worked at the Stanford Cancer Institute Transgenic, Knockout and Tumor model Center (TKTC) as a group lead and preclinical oncology facility manager. She is currently a program manager and associate director of business development at SPARK since 2019.
SPARK Taiwan 閮颲血摰�
蝢滬� 撠���� | 02-2737-7833 | sparktw@narlabs.org.tw
Copyright 穢 SPARK TAIWAN. All rights reserved.